# organic papers

Acta Crystallographica Section E Structure Reports Online

ISSN 1600-5368

# Gu-Ping Tang<sup>a</sup>\* and Jian-Ming Gu<sup>b</sup>

<sup>a</sup>College of Life Science, Zhejiang University, Hangzhou, Zhejiang 310028, People's Republic of China, and <sup>b</sup>Centre of Analysis and Measurement, Zhejiang University, Hangzhou, Zhejiang 310028, People's Republic of China

Correspondence e-mail: tangguping@yahoo.com.cn

#### **Key indicators**

Single-crystal X-ray study T = 253 K Mean  $\sigma$ (C–C) = 0.003 Å Disorder in main residue R factor = 0.047 wR factor = 0.089 Data-to-parameter ratio = 14.6

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e. *N*-[4-Cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenylsulfanyl)-2-hydroxy-2-methylpropionamide chloroform solvate

The title compound,  $C_{18}H_{14}F_4N_2O_2S \cdot CHCl_3$ , forms a onedimensional hydrogen-bonded chain *via* a single  $O-H \cdots N$ interaction; the chain runs approximately along the [110] axis. The two benzene rings are almost parallel to one another, forming a dihedral angle of 8.43 (8)°. Received 1 August 2005 Accepted 5 September 2005 Online 14 September 2005

## Comment

The title compound, (I), was prepared as an intermediate in the synthesis of bicalutamide [trademark name for *N*-(4cyano-3-trifluoromethylphenyl)-3-(4-fluorobenzensulfonyl)-2-hydroxy-2-methylpropionamide], a nonsteroidal antiandrogen which acts on the male hormones (androgens) but which has no steroidal effects (Tucker *et al.*, 1988; Xiao *et al.*, 2003).



The crystal structure of (I) comprises one N-(4-cyano-3-trifluoromethylphenyl)-3-(4-fluorophenylsulfanyl)-2hydroxy-2-methylpropionamide molecule and one CHCl<sub>3</sub> solvent molecule. The solvent molecule is disordered. The two benzene ring mean planes are almost parallel to each other, forming a dihedral angle of 8.43 (8)°.

Intermolecular  $O-H\cdots N$  hydrogen bonds (Table 2) link the molecules into infinite chains, parallel to the [110] axis. Atom O1 belonging to the hydroxy group acts a donor, while N2 atom of the cyano group serves as an acceptor. Because of this hydrogen-bond interaction, the cyano group deviates slightly from the plane of the benzene ring (C5–C8/C10/C12); the deviations of atoms C9 and N2 from the mean plane are 0.123 and 0.250 Å, respectively. The cyano group is unconjugated with the benzene ring, resulting in a C8–C9 bond length of 1.448 (3) Å, which is long compared with the value expected for a formal  $Csp^2-Csp$  bond (Allen *et al.*, 1987). The chain is further stabilized by weak intermolecular N1– H1 $\cdots$ O1 interactions (Table 2) to form layers in the crystal structure.

© 2005 International Union of Crystallography Printed in Great Britain – all rights reserved





A view of (I), with displacement ellipsoids drawn at the 30% probability level and H atoms shown as small circles of arbitrary radii. The minor component disordered Cl atoms in the solvent and F atoms in the  $CF_3$  group are depicted with unshaded ellipsoids and dashed bonds.



#### Figure 2

A chain of molecules in (I). Hydrogen bonds are represented with dashed lines. [Symmetry codes: (i) 1 + x, 1 + y, z; (ii) -1 + x, -1 + y, z.]

### **Experimental**

2-Hydroxy-2-methyl-3-p-tolylsulfanylpropionic acid (36.5 g, 159 mmol), 2-trifluoromethyl-4-aminobenzonitrile (38.0 g, 200 mmol) and N,N-dimethyl acetamide (300 ml) were mixed in a 500 ml threenecked bottle and stirred at 263 K. Thionyl chloride (12 ml, 164 mmol) was then added dropwise to the solution and the resulting mixture was kept for 30 min at 258-263 K and then allowed to react for 24 h. After that time, the reaction solution was poured into icewater (600 ml) and extracted with  $CH_2Cl_2$  (4 × 300 ml). The organic part was washed with HCl (3 M, 4  $\times$  300 ml), NaCl (saturated solution,  $2 \times 150$  ml), NaHCO<sub>3</sub> (saturated solution,  $3 \times 150$  ml) and NaCl (saturated solution,  $2 \times 150$  ml), and dried over anhydrous MgSO<sub>4</sub>. Compound (I) was recovered after vacuum distillation. The final product was recrystallized from a mixture of toluene and petroleum ether (5:1) (yield 26 g, 41%) (Thurlow, 1998; Sepp-Lorenzino & Slovin, 2000). Finally, compound (I) was recrystallized from chloroform, giving colourless crystals suitable for X-ray diffraction.

$C_{18}H_{14}F_4N_2O_2S\cdot CHCl_3$	Z = 2
$M_r = 517.75$	$D_x = 1.561 \text{ Mg m}^{-3}$
Triclinic, P1	Mo $K\alpha$ radiation
$a = 8.8442 (9) \text{ Å}_{1}$	Cell parameters from 4876
$p = 10.4591 \ (9)$ Å	reflections
e = 13.319 (1) Å	$\theta = 2.2-27.5^{\circ}$
$\alpha = 110.718 \ (4)^{\circ}$	$\mu = 0.56 \text{ mm}^{-1}$
$B = 90.895 \ (2)^{\circ}$	T = 253 (1) K
$\nu = 105.595 \ (2)^{\circ}$	Block, colourless
$V = 1101.5 (2) \text{ Å}^3$	$0.42 \times 0.33 \times 0.28 \text{ mm}$

#### Data collection

Rigaku R-AXIS RAPID diffractometer  $\omega$  scans Absorption correction: multi-scan (*ABSCOR*; Higashi, 1995)  $T_{\min} = 0.738, T_{\max} = 0.854$ 9744 measured reflections

### Refinement

Refinement on  $F^2$   $R[F^2 > 2\sigma(F^2)] = 0.047$   $wR(F^2) = 0.089$  S = 0.964892 reflections 334 parameters

#### 4896 independent reflections 3260 reflections with $F^2 > 2\sigma(F^2)$ $R_{int} = 0.025$ $\theta_{max} = 27.5^{\circ}$ $h = -11 \rightarrow 11$ $k = -13 \rightarrow 13$ $l = -17 \rightarrow 17$

H-atom parameters constrained  $w = 1/[0.0002F_o^2 + 3\sigma(F_o^2) + 0.5]/(4F_o^2)$   $(\Delta/\sigma)_{max} = 0.010$   $\Delta\rho_{max} = 0.39 \text{ e} \text{ Å}^{-3}$  $\Delta\rho_{min} = -0.38 \text{ e} \text{ Å}^{-3}$ 

# Table 1 Selected bond lengths (Å).

S1-C1	1.801 (3)	O2-C4	1.218 (2)
S1-C13	1.769 (2)	N2-C9	1.137 (3)
O1-C2	1.425 (2)	C8-C9	1.448 (3)

# Table 2 Hydrogen-bond geometry (Å, °).

1

$\begin{array}{c ccccccccccccccccccccccccccccccccccc$					
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$D = H \cdots A$	D-H	$H \cdot \cdot \cdot A$	$D \cdots A$	$D - \mathbf{H} \cdots A$
	$D1 - H101 \cdots N2^{i}$ $V1 - H111 \cdots O1^{ii}$	0.90 0.86	2.06 2.51	2.957 (3) 3.094 (3)	175 126

Symmetry codes: (i) +x - 1, +y - 1, +z; (ii) -x + 1, -y, -z.

The Cl atoms of the chloroform molecule and the F atoms of the CF<sub>3</sub> group were found to be disordered. Each atom was split over two sites and the site occupancy factors were refined with the sums constrained to 1, and then fixed at at the final stage. H atoms belonging to the hydroxy and amido groups and to the CHCl<sub>3</sub> molecule were located in difference maps and included in the refinement with as-found constrained O–H, N–H and C–H bond lengths. Other H atoms were placed in calculated positions and refined using a riding model. Constrained C–H bond lengths are 0.98 Å for aromatic CH, 0.97 Å for methylene CH<sub>2</sub> and 0.96 Å for methyl CH<sub>3</sub>. For all H atoms,  $U_{iso}(H)$  values were initially refined and then fixed in the final cycles.

Data collection: *PROCESS-AUTO* (Rigaku, 1998); cell refinement: *PROCESS-AUTO*; data reduction: *CrystalStructure* (Rigaku/ MSC, 2004); program(s) used to solve structure: *SIR97* (Altomare *et al.*, 1999); program(s) used to refine structure: *CRYSTALS* (Betteridge *et al.*, 2003); molecular graphics: *ORTEP-3 for Windows* (Farrugia, 1997); software used to prepare material for publication: *CrystalStructure*.

### References

- Allen, F. H., Kennard, O., Watso, D. G., Brammer, L., Orpen, A. G. & Taylor, R. (1987). J. Chem. Soc. Perkin Trans. 2, 1–19.
- Altomare, A., Burla, M. C., Camalli, M., Cascarano, G., Giacovazzo, C., Guagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). J. Appl. Cryst. 32, 115–119.
- Betteridge, P. W., Carruthers, J. R., Cooper, R. I., Prout, K. & Watkin, D. J. (2003). J. Appl. Cryst. 36, 1487.
- Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.

Higashi, T. (1995). ABSCOR. Rigaku Corporation, Tokyo, Japan.

- Rigaku (1998). PROCESS-AUTO. Version 1.06. Rigaku Corporation, Tokyo, Japan.
- Rigaku/MSC (2004). CrystalStructure. Version 3.6.0. Rigaku/MSC, 9009 New Trails Drive, The Woodlands, TX 77381-5209, USA.
- Sepp-Lorenzino, L. & Slovin, S. (2000). Exp. Opin. Ther. Patents, 10, 1833-1842.
- Thurlow, R. J. (1998). Emerging Drugs, 3, 225-246.
- Tucker, H., Crook, J. W. & Chesterson, G. J. (1988). J. Med. Chem. 31, 954–959.
   Xiao, T., Zhang, X. Q., Tian, C. M. & Wang, J. T. (2003). Chin. J. Synth. Chem. 11, 346–348.